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Abstract Late diagnosis of hepatocarcinoma (HCC) is one
of the most primary factors for the poor survival of patients.
Thereby, identification of sensitive and specific biomarkers
for HCC early diagnosis is of great importance in biological
medicine to date. In the present study, serum metabolites
of the HCC patients and healthy controls were investi-
gated using the improved liquid chromatography–mass
spectrometry (LC/MS). A wavelet-based method was
utilized to find and align peaks of LC–MS. The
characteristic peaks were selected by performing a two-
sample t test statistics (p value <0.05). Clustering analysis
based on principal component analysis showed a clear
separation between HCC patients and healthy individuals.
The serum metabolite, namely 1-methyladenosine, was
identified as the characteristic metabolite for HCC. More-
over, receiver–operator curves were calculated with 1-
methyladenosine and/or alpha fetal protein (AFP). The
higher area under curve value was achieved in 1-
methyladenosine group than AFP group (0.802 vs. 0.592),
and the diagnostic model combining 1-methyladenosine
with AFP exhibited significant improved sensitivity,
which could identify those patients who missed the
diagnosis of HCC by determining serum AFP alone.
Overall, these results suggested that LC/MS-based
metabonomic study is a potent and promising strategy
for identifying novel biomarkers of HCC.
Keywords Biomarker.Liquid chromatography–mass
spectrometry.Metabonomics.Hepatocarcinoma
Introduction
Metabonomics that was defined as a powerful quantitative
tool and employed toward the understanding of global
systems biology has become widespread in recent years [1].
It mainly focuses on the comprehensive and semi-
quantitative study of metabolites in a biological system at
a specified time in specific environmental conditions [2]. In
contrast to genomics, transcriptomics, and proteomics,
which address macromolecules with similar chemical
properties, such as DNA, RNA, and proteins, metabonomics
analysisdealswithdiversepropertiesoflowmolecularweight
bio-compounds. It has been shown to be an effective tool
for biomarker screening [3–6], disease diagnosis and
prognosis [7–10], and characterization of metabolic
network [11, 12]. As metabonomics is the downstream
product of genomics and proteomics, it is also regarded as
the complement of other “omics” for interpretation of gene
functions (functional genomics) [11, 13].
Metabonomic studies generally employ such techniques
as nuclear magnetic resonance spectroscopy, Fourier-
transform infrared (FT/IR) spectroscopy, and gas chroma-
tography/mass spectrometry (GC/MS) or liquid chromatog-
raphy (LC)/MS [14]. Among them, LC/MS is regarded as
the most powerful technology in drug metabolites analysis.
Recently, it has been considered as an ideal tool for the
screening of metabolites and biomarkers [15], for its
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tative analysis, and the ability to analyze biofluids with
extreme molecular complexity. Some potential bio-
markers in serum and urine of cancer patients have
been successfully identified by applying LC/MS-based
technology [16, 17].
Hepatocarcinoma (HCC) is among the leading causes
of cancer death globally. Late diagnosis of HCC is the
key factor for the poor survival of patients. To date, the
vast majority of HCC patients are firstly identified by
imaging or serological method. However, the resolution
and accuracy of current imaging facility remain disap-
pointingly low for HCC early diagnosis. The sensitivity
of the most common used HCC biomarker, alpha fetal
protein (AFP), is limited to ∼70% in clinic. The liver is
the most important metabolic organ in the human body,
and the metabolic profile variation was accepted to occur
prior to the image diagnosis in HCC patients. Herein, we
examined the serum metabolites patterns of HCC patients
and normal controls by performing LC/MS methods, and
identified some potential biomarkers which might be
applied to distinguish HCC patients from healthy
individuals at early stage.
Experiments and methods
Patient recruitment and sample collection
Informed consent and ethical committee approval was
obtained from every participant. Thirty-eight healthy
participants and 41 hospitalized patients with histopatho-
logically confirmed HCC in First Affiliated Hospital of
Zhejiang University were enrolled in this study. The
average age is 55 years old in patients and 35 years old in
healthy controls. In patients, ratio of male to female is
approximately 2:1, and in healthy controls, the ratio is
nearly 1.7:1. Serum samples were collected in the depart-
ment of laboratory medicine of the hospital, and the levels
of ALT, AFP , and HBV-DNA were determined. Olympus
Au560 automatic biochemistry analyzer was applied to
measure the level of serum alanine amino transferase
(ALT). Serum AFP level was tested by enzyme-linked
immunosorbent assay according to the manufacturer’s
protocol (Bio-Rad, USA). HBV (hepatitis B virus)-DNA
load in serum was quantified by real-time polymerase chain
reaction (PCR) assays using ABI PRISM 7300 sequence
detector (Applied Biosystems, USA).
Sera specimen pretreatment
Prior to LC/MS analysis, 200 μL of acetonitrile was added
to 200 μL of the serum samples and vortex vigorously for
2 min. The sample mixture was allowed to stand for 5 min
and centrifuged at 13,000 rpm for 10 min at 4 °C. The
supernatant was then concentrated to complete dryness in a
turbovap nitrogen evaporator (Zymax corp. USA). Sixty
microliters of a mixture of acetonitrile–water (1:1, v/v) was
added to each of the dried serum extracts, vortex-mixed for
1 min, and subsequently centrifuged at 13,000 rpm for
10 min at 4 °C. Fifty microliters supernatant was then
subjected to LC/MS analysis.
Liquid chromatography separation
Chromatographic separation was performed on an Acquity
UPLCTM system (Waters Corp., USA) equipped with a 2.1×
50-mm symmetry C18 reversed-phase column with BEH
(ethylene-bridged hybrid) particle size 1.7 μm (Milford, MA,
USA). The mobile phase was a mixture of acetonitrile–
water (1:1, v/v) buffer containing 0.1% formic acid. The
column was equilibratedand eluted under isocratic conditions
withaflowrateof0.2mL/min.Thecolumnwasmaintainedat
4 °C, and the injection volume was 5 μL.
Fig. 1 Representative LC/MS
total ion chromatograms of
serum sample from a normal
individual and a HCC patient
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AM S –MS mass spectrometer (Quattro Premier XE, Waters
Corp., USA) was employed for analysis of metabolite ions.
Ionization was achieved using electrospray in the positive
mode with the spray voltage set at 3,000 V . Nitrogen was
used as nebulizer gas, and nebulizer gas was delivered at a
flow rate of 16 L/h with a source temperature of 120 °C.
Desolvation gas (nitrogen) was heated to 250 °C and
delivered at a flow rate of 400 L/h. Masses were acquired
from m/z200 to 2,000.
Data processing and pattern recognition
The experimental data of LC/MS were reformed into a
matrix including time, ion mass (m/z), and intensity.
Baseline correction and peak finding were carried out by
using our matlab code (MA TLAB 7.0, MathWorks, USA).
Maximal spectrum of continuous wavelet transform
(MSCWT) was employed to correct baseline and detect
peak positions [18]. The peak alignment was carried out
utilizing the method described in literature [19]. The MS
analysis system was applied to identify the characteristic
metabolite corresponding to the featured peak in database
of Metlin (http://metlin.scripps.edu)[ 20] and HMDB
(http://www.hmdb.ca/)[ 21]. The hit metabolites were
verified by text mining techniques.
Principal component analysis (PCA) was performed to
cluster the samples (MA TLAB software, MathWorks,
USA). The score plots allowed the visualization of data
and compared samples between the test group and control
group. Diagnostic model was constructed with the marker
metabolites alone or combining AFP , using linear
discrimination analysis method. The classification perfor-
mance (specificity and sensitivity) was assessed by ACC
value of the receiver operating characteristic (ROC) curves.
Results and discussion
Comparison of transaminase, AFP , and HBV-DNA load
between HCC patients and healthy controls
The elevation of serum ALT and AST (aspartate amino-
transferase) indicates the liver injury, which could be
caused by hepatitis virus infection, drugs abuse, toxins
intake, or hepatic ischemia–reperfusion. Serum ALT level
of the control group was lower than that of HCC group
(11.71±6.26 vs. 69.84±60.04, p<0.01). Similar result was
also achieved on the level of serum AST (18.13±6.42 vs.
109.22±99.28, p<0.05). Elevation of ALT and AST might
be due to the infection of HBV , whereas there was no
significant difference on the HBV-DNA load between high
and low ALT subgroups of HCC patients (p>0.05, t test).
Moreover, the serum levels of AFP were measured in HCC
patients and healthy controls. The positive rate of AFP in
the patients of HCC group was 75% with the cut-off value
setting as 20 ng/mL [22], and none was positive in the
Table 1 The characteristic peaks of HCC samples
Peak retention time p value (t test) Distance (HCC and normal)
2.78 4.11E−24 0.13126995
2.947 2.01E−20 0.028912113
6.412 1.04E−16 0.007838236
6.542 3.70E−18 0.138559594
6.579 5.98E−18 0.004900794
6.653 2.57E−18 0.072035253
6.672 3.11E−19 0.088778169
6.764 2.60E−19 0.009222483
7.246 2.06E−19 0.16321364
7.358 1.71E−19 0.016046921
Fig. 2 Relative serum levels of the three characteristic peaks in HCC
and normal samples
Fig. 3 T-test scores plot discriminating HCC samples from normal
controls based on the raw data of peaks 6.653, 6.764, and 7.358. Blue
dot: normal sample; red dot: HCC samples
Identification of serum biomarkers of hepatocarcinoma 1901patients of control group. It should be noted that 25% of the
patients missed the diagnosis of HCC when AFP measure-
ment was performed alone. Therefore, it is necessary to
identify one or more biomarkers to improve the laboratory
diagnosis of HCC. We expected that some serum metabolites,
which were influenced by impaired hepatic function [23],
might be developed as the diagnostic biomarker for HCC.
Distinct serum metabonomic profiles of HCC patients
Representative chromatogram of a case from control group
was shown in Fig. 1. Following baseline correction and
peak alignment, metabolites signals were obtained in all.
T-score method [24]w a sa p p l i e dt oi d e n t i f yt h ef e a t u r e d
peaks that were different between HCC patients and the
control individuals. All of the peaks were sorted with p
value of t test. Top ten peaks that possess the least p value
were considered as featured peaks (Table 1). For those
featured peaks, the p values were far less than the
significant difference level (p<0.05). Intriguingly, each
of the three metabolites represented by the fore three
featured peaks (6.653, 7.358, and 6.764 min) displayed a
significant elevated level in HCC patients compared with
Fig. 4 (a) PC scores plot discriminating HCC samples from normal
controls based on ten characteristic peaks. Blue dot: normal sample;
red dot: HCC samples. (b) The first three principal components have a
contribution ratio of 94.42%
Fig. 5 (a) Mass spectrum analysis of the metabolite corresponding
to the peak at 7.358 min. (b) The molecular formula of
1-methyladenosine
Table 2 Serum metabolites of characteristic peaks of HCC samples
Peak m/z Metabolite
6.653 249 Unknown
6.764 229 Unknown
7.358 281 1-Methyladenosine
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analysis of the three peaks further confirmed that they
were true signal (SNR≥3) instead of noise (SNR≈1) and
were detectable by MS (SNR7.358=7.9, SNR6.653=3.4,
SNR6.764=4.4) [25, 26]. More importantly, samples of HCC
and control groups could be well separated using the three
featured peaks together, which suggests that these metabo-
lites might be potential HCC biomarkers in serum (Fig. 3).
PCA is an unsupervised projection method usually used
in clustering samples [27, 28]. In this work, PCAwas also
employed in clustering the LC/MS data, and the scores plot
of the first three principal components that were in line with
the peak 6.653, 7.358, and 6.764 was shown in Fig. 4a.
HCC samples and the controls were well clustered in the
score plot. The sum contribution ratio of the fore three
peaks was more than 0.94 (Fig. 4b), which indicates that
joint application of the three peaks is sufficient in
differentiating HCC patients from healthy individuals.
V alidation of 1-methyladenosine as potential biomarker
of HCC
In metabonomic studies, identification of biomarkers that
can differentiate patients from healthy individuals in
clinical test is of great value. With this report, we
combined database searching with literature mining in
inferring the metabolites corresponding to the featured
peaks. The inferred metabolites that were indicated by
the first three featured peaks were shown in Table 2.
There was no matched metabolite for peak 6.653 and
6.764 in databases of Metlin. As shown in Fig. 5,t h e
molecular ion of the metabolite at 7.358 min peaked at
282m/z and the intensity fraction peaked at 150m/z,
exhibiting a well match to the mass spectrum of 1-
methyladenosine in HMDB (http://www.hmdb.ca/). The
result of literature mining in PubMed suggested that 1-
methyladenosine is associated with liver cancer (PMID:
19399767, 7562399, 1823269, 3711674, and 7139605).
Collectively, our data indicated that 1-methyladenosine
could be a potential serum biomarker for HCC.
To validate the significance of 1-methyladenosine as a
potential HCC biomarker, ROC curve is plotted assuming the
levels of 1-methyladenosine follow a normal distribution in
two groups. Area under the curve (AUC) is calculated using
the trapezoidal rule. As shown in Fig. 6a, b,1 -
methyladenosine displayed higher AUC value than that of
AFP or HBV-DNA. Furthermore, combination of 1-
methyladenosine and AFP achieved the highest AUC value
of 0.95. These data implied that the new diagnostic model
combining 1-methyladenosine with AFP possesses improved
sensitivity and could identify those patients who missed the
diagnosis of HCC by determining serum AFP alone.
Clinical correlation of 1-methyladenosine
1-Methyladenosine is a methylated nucleotide containing
purine bases. The modifications are the results of the
catalytic reaction triggered by the methylation-associated
enzymes. The urine levels of 1-methyladenosine has been
reported to be higher in preoperative patients with ovarian
or breast cancer [29, 30]. However, no significant difference
of 1-methyladenosine was found in urine between HCC
patients and healthy controls [31]. In the present study,
receiver–operator curves were calculated with serum 1-
methyladenosine and/or AFP . The higher ACC value was
achieved in 1-methyladenosine group than AFP group, and
Fig. 6 (a) ROC analysis was performed using the values of 1-
methyladenosine, AFP , HBV-DNA, or 1-methyladenosine plus
AFP . The normal distribution functions of two groups (HCC and
control) were established by estimating mean and variance, with
which the receiver–operator characteristic (ROC) curve was
plotted
Identification of serum biomarkers of hepatocarcinoma 1903the diagnostic model combining 1-methyladenosine with
AFP showed significant improved sensitivity, which could
identify the patients missed the diagnosis of HCC by
determining serum AFP alone. Thus, higher levels of serum
methyladenosine should been regarded as the additional
diagnostic marker for HCC, in particular, combined with
the determination of serum AFP . Levels of methylated
purines were found to be elevated in cancer patients due
to the presences of hyperactive methyltransferases [32].
Therefore, the increase of 1-methyladenosine in HCC
samples may be due to the hyperactivation of methyl-
transferases, which was followed by the nucleotides
modification in response to inflammatory stress or
oxidative DNA damage.
Conclusion
LC/MS method has been proven to be a powerful and
reliable analytic platform for serum or plasma metabolites
screening with relative high sensitivity. A LC/MS-based
integrated analytical method was developed in this study to
identify the characteristic metabolites which have the
capability to distinguish HCC patients from healthy
individuals. As a result, 1-methyladenosine achieved high
AUC value of 0.90 and was characterized as the potential
biomarker of HCC. Furthermore, the combination of 1-
methyladenosine and AFP even achieved the AUC value up
to 0.95. These data suggested that the metabolites may be
identified as potential HCC biomarkers, and some of which
could be applied in the screening of HCC high-risk
population or the early diagnosis of patients in clinic.
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